Genentech Reports Sales Growth; Remains Hopeful About Avastin Approval For Breast Cancer
This article was originally published in The Pink Sheet Daily
While its pipeline largely consists of line extensions, firm touts 15 novel compounds added during 2006-2007.
You may also be interested in...
Oncologic Drugs Advisory Committee expresses concerns about overall survival, toxicity and study conduct.
Firm would bid on remaining rights to Rituxan should a change of control occur at Biogen Idec, CFO Ebersman says during third quarter call .
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.